Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The J&J/ Vanderbilt Tie-Up: Accessing Innovation On The Cheap

This article was originally published in Start Up

Executive Summary

With most Big Pharmas facing a steep and costly patent chasm and in-house R&D failing to produce the necessary bridge to patent-challenged franchises, companies have been forced to look for new sources of innovation beyond traditional in-licensing and acquisition. As a result, some drugmakers are looking with renewed interest at the innovation housed in universities. The tie-up between Johnson & Johnson and Vanderbilt University is just the latest example of this important trend.

You may also be interested in...



Vanderbilt's Neuroscience Unit Operates Like A Biotech

A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.

Vanderbilt's Neuroscience Unit Operates Like A Biotech

A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.

Vanderbilt Research Into GlyT1 Inhibition May Result In New Approach To Treating Schizophrenia

Vanderbilt's Center for Neuroscience Drug Discovery licenses three preclinical GlyT1 candidates to Karuna Pharmaceuticals, one of three business development actions by the center in recent weeks.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091740

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel